The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be (link sends e-mail)
| To be included in this study, subjects must have completed the placebo controlled phase 3 study of PTC (PTC124-GD-009) | |
| Study Name on ClinicalTrials.gov (link is external) | Extension Study of Ataluren TM (PTC124) in cystic Fibrosis |
|---|---|
| Study Drug | Ataluren TM (PTC124) |
| Type of Study Drug | CFTR Modulation |
| Study Title | A Phase 3 Efficacy and Safety Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis |
| Study Phase | 3 |
| Study Sponsor | PTC Therapeutics |
http://clinicaltrials.gov/ct2/show/NCT01140451 (link is external) | |
| Participating ECFS-CTN sites | University Hospital Leuven Hôpital Cochin Hôpital Necker – Enfants Malades Klinikum der Universität Köln Azienda Ospedaliera di Verona Universitair Medisch Centrum Utrecht Karolinska University Hospital, Huddinge |
| Age | 6 years and older |